The development of a generic liposomal doxorubicin product requires the study of critical physicochemical properties of the formulation. Food and Drug Administration (FDA) draft guideline has suggested few parameters to be tested for in vitro bioequivalence study which include liposomal composition, state of encapsulated drug, internal environment, liposomal morphology and number of lamellae, lipid bilayer phase transition, liposomal size distribution, grafted Polyethylene Glycol (PEG) at liposomal surface, electric surface potential or charge and in vitro leakage under multiple conditions. Characteristic features of components of liposomal doxorubicin formulation and detail of parameters to be studied have been discussed. This review compi...
Liposomes are nano-sized lipid bilayer vesicles of great interest in drug delivery. Doxil® is a...
Cancer remains a major cause of hospitalization and death every year. From time to time, new formula...
More than 20 years after its approval by the Food and Drug Administration (FDA), liposomal doxorubic...
The development of a generic liposomal doxorubicin product requires the study of critical physicoche...
The Present studies is Liposomes have been used to target drug to specific organs, delay the loss of...
Two liposomal formulations of doxorubicin (Caelyx® and Doxopeg®) were evaluated for phospholipid con...
Introdution: Common cancer treatment methods have many side effects. Therefore, the use of new metho...
The toxicity and efficacy properties of doxorubicin entrapped inside liposomes are sensitive to the ...
have a narrow therapeutic index. In fact, in some patients, the onset of serious adverse effects may...
BACKGROUND. Compared with free drug, sterically stabilized liposomal drug has prolonged circulation ...
Doxorubicin hydrochloride is an anticancer medicine for treatment of various kind of cancer. Antican...
Doxorubicin is an effective anticancer drug used in the treatment of several cancers such as osteosa...
Cancer is a leading cause of death in the world; consequently, an increasing number of studies have ...
An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) an...
Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumor...
Liposomes are nano-sized lipid bilayer vesicles of great interest in drug delivery. Doxil® is a...
Cancer remains a major cause of hospitalization and death every year. From time to time, new formula...
More than 20 years after its approval by the Food and Drug Administration (FDA), liposomal doxorubic...
The development of a generic liposomal doxorubicin product requires the study of critical physicoche...
The Present studies is Liposomes have been used to target drug to specific organs, delay the loss of...
Two liposomal formulations of doxorubicin (Caelyx® and Doxopeg®) were evaluated for phospholipid con...
Introdution: Common cancer treatment methods have many side effects. Therefore, the use of new metho...
The toxicity and efficacy properties of doxorubicin entrapped inside liposomes are sensitive to the ...
have a narrow therapeutic index. In fact, in some patients, the onset of serious adverse effects may...
BACKGROUND. Compared with free drug, sterically stabilized liposomal drug has prolonged circulation ...
Doxorubicin hydrochloride is an anticancer medicine for treatment of various kind of cancer. Antican...
Doxorubicin is an effective anticancer drug used in the treatment of several cancers such as osteosa...
Cancer is a leading cause of death in the world; consequently, an increasing number of studies have ...
An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) an...
Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumor...
Liposomes are nano-sized lipid bilayer vesicles of great interest in drug delivery. Doxil® is a...
Cancer remains a major cause of hospitalization and death every year. From time to time, new formula...
More than 20 years after its approval by the Food and Drug Administration (FDA), liposomal doxorubic...